Universal Chimeric Antigen Receptors for T-Cell Cancer Therapy

Case ID:
UA19-268
Invention:

This invention is a patient-specific "Universal" Chimeric Antigen Receptor T-cell therapy that uses CAR T cells which target a universal "flag", such as a peptide, protein, or small molecule. The "Universal" CAR T cells are linked to "adapter" molecules or particles which have been designed to bind to patient-specific T-cells.

 

Background:

Chimeric Antigen Receptor (CAR) T-cell therapy is a form of immunotherapy wherein T-cells are designed to attack cancer cells, currently used most often to treat blood or lymphatic cancers. This process is costly, time consuming, not possible for all patients, and can have very severe off-target effects.

 

Applications:

  • Cancer immunotherapy

 

Advantages:

  • Enables CAR T-cell therapy to be
    • Faster
    • Cheaper
    • More widely available
    • Safer
    • Better standardized
    • More flexible
Patent Information:
Contact For More Information:
Jonathan Larson
Senior Licensing Manager, College of Science
The University of Arizona
jonathanlarson@arizona.edu
Lead Inventor(s):
Michael Worobey
Keywords: